The U.S. government’s premier research body has made an important discovery that could help create new drugs to lower “bad” cholesterol, and hopefully prevent heart attacks and stroke. But the ...

Scientists have made a significant breakthrough in understanding how 'bad' cholesterol, known as low-density lipoprotein-cholesterol or LDL-C, builds up in the body. The researchers were able to show ...

PITTSBURGH, Oct. 30, 2025 – An international team led by a University of Pittsburgh School of Medicine scientist has created a first-of-its-kind resource to identify those with a genetic risk for ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package insert ...

High levels of low-density lipoprotein (LDL) cholesterol can cause artery blockages and diseases like heart attacks and strokes. Further, it raises the risk of cardiovascular disease (CVD). Thickened ...

Researchers have presented the interim results of a clinical trial that used a single infusion of CRISPR gene-editing technology to permanently switch off low-density lipoprotein cholesterol ...

Study deciphers the molecular handshake between LDL receptors and apoB100, shedding light on cholesterol metabolism and its role in cardiovascular disease. Study: Structure of apolipoprotein B100 ...

Pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) are produced in large quantities locally in the joints and subsequently enter the bloodstream. TNF-α and IL-6 may promote LDL metabolism by ...

Cardiovascular disease (CVD) remains the leading cause of death globally. Hypercholesterolemia is a major modifiable risk factor for developing atherosclerotic CVD (ASCVD). Although statins are the ...

An investigational drug, currently known as AZD0780, lowers low-density-lipoprotein cholesterol (LDL-C) to target levels in most patients whose cholesterol is still over target despite statin therapy, ...

From its perch on the cell surface, low-density lipoprotein (LDL) receptor-related protein 2 (LRP2) somehow manages to nab ligands, bring them to the endosome, drop them off, and return to the cell ...